David J. Matlin - Aug 10, 2023 Form 4 Insider Report for TriSalus Life Sciences, Inc. (TLSI)

Role
Director
Signature
/s/ Sean Murphy, Attorney-in-Fact for David J. Matlin
Stock symbol
TLSI
Transactions as of
Aug 10, 2023
Transactions value $
$1,000,000
Form type
4
Date filed
8/14/2023, 05:58 PM
Previous filing
Jun 20, 2023
Next filing
Sep 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TLSI Common Stock Other +932K 932K Aug 10, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TLSI Redeemable Warrants Other $0 +1.24M $0.00 1.24M Aug 10, 2023 Common Stock 1.24M $11.50 Direct F2, F3
transaction TLSI Stock Option (right to buy) Award $0 +35K $0.00 35K Aug 10, 2023 Common Stock 35K $11.34 Direct F4
transaction TLSI Series A Preferred Stock Award $1M +100K $10.00 100K Aug 10, 2023 Common Stock 100K $10.00 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of Common Stock received as a pro rata distribution for no consideration from MedTech Acquisition Sponsor LLC ("Sponsor") in accordance with the terms of the Sponsor's limited liability company agreement. In prior reports, the Reporting Person reported beneficial ownership of 6,250,000 shares of Issuer's Common Stock held by the Sponsor, of which the Reporting Person is a managing member.
F2 Represents warrants received as a pro rata distribution for no consideration from the Sponsor in accordance with the terms of the Sponsor's limited liability company agreement.
F3 The redeemable warrants expire on August 10, 2028, or earlier upon redemption or liquidation.
F4 The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of August 10, 2023, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
F5 The Series A Convertible Preferred Stock ("Preferred Stock") is convertible, in whole or in part, into 100,000 shares of Common Stock of the Issuer (based on an initial conversion price of $10.00 per share, which is subject to adjustment upon the occurrence of certain events, the "Conversion Price") at any time, at the Reporting Person's election. The number of shares of the Issuer's Common Stock received per share of Preferred Stock upon conversion equals the sum of (A) $10.00 (as adjusted upon the occurrence of certain events) and (B) any accrued, unpaid annual dividends, divided by the Conversion Price, with cash in-lieu of fractional shares. All then outstanding shares of Preferred Stock are automatically converted into shares of the Issuer's Common Stock on August 10, 2027.